SCTI is currently earning revenue from its stem cell sales outside of the U.S. Growth plans include: expansion of manufacturing facility; increased sales to clinics, university and private labs and physicians globally; seek research funding from government health agencies; acquire technologies from government health agencies; increased R&D spending; and licensing of technology to appropriate partners.

SCTI has a manufacturing facility in Europe;

Use of stem cell transplants has no known side effects in patients, and does not require immunosuppression to prevent rejection of the stem cells;

Market leader, based on more than 25 years of R&D; and

In a study published February 1, 2003, D&MD Publications, provider of market analysis, opportunity assessment and tactical guidance for the life sciences market, forecasts that the cell therapy market will near $30 billion by 2010.

According to an editorial in Red Herring, February 2003, “Stem cell therapies are poised to capture what could be the biggest new market to hit biotech in a decade.... that could grow to $25 billion in the next three to five years - nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys.”

California’s Proposition 71 allocates $3 billion in funding for stem cell R&D..

According to the Web site of the American Diabetes Association, it estimates that nearly 18.2 million people, or 6.3 percent of the U.S. population, currently have diabetes.